Syros Pharmaceuticals Statistics
Total Valuation
SYRS has a market cap or net worth of 21,466. The enterprise value is 1.97 million.
| Market Cap | 21,466 |
| Enterprise Value | 1.97M |
Important Dates
The last earnings date was Friday, October 31, 2025.
| Earnings Date | Oct 31, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
SYRS has 26.83 million shares outstanding.
| Current Share Class | 26.83M |
| Shares Outstanding | 26.83M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.17% |
| Owned by Insiders (%) | 0.57% |
| Owned by Institutions (%) | 2.00% |
| Float | 26.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.06 |
| PB Ratio | -0.00 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.02 |
| EV / Sales | 5.11 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.02 |
Financial Position
The company has a current ratio of 2.25
| Current Ratio | 2.25 |
| Quick Ratio | 2.05 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.60 |
| Interest Coverage | -20.92 |
Financial Efficiency
Return on equity (ROE) is -776.96% and return on invested capital (ROIC) is -94.28%.
| Return on Equity (ROE) | -776.96% |
| Return on Assets (ROA) | -59.88% |
| Return on Invested Capital (ROIC) | -94.28% |
| Return on Capital Employed (ROCE) | -197.02% |
| Revenue Per Employee | 5,676 |
| Profits Per Employee | -1.44M |
| Employee Count | 68 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.96% in the last 52 weeks. The beta is 1.15, so SYRS's price volatility has been higher than the market average.
| Beta (5Y) | 1.15 |
| 52-Week Price Change | -99.96% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.05 |
| Relative Strength Index (RSI) | 44.99 |
| Average Volume (20 Days) | 35,974 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.60 |
Income Statement
In the last 12 months, SYRS had revenue of 386,000 and -97.82 million in losses. Loss per share was -2.66.
| Revenue | 386,000 |
| Gross Profit | -88.25M |
| Operating Income | -111.52M |
| Pretax Income | -97.82M |
| Net Income | -97.82M |
| EBITDA | -110.18M |
| EBIT | -111.52M |
| Loss Per Share | -2.66 |
Balance Sheet
The company has 58.28 million in cash and 60.23 million in debt, giving a net cash position of -1.95 million or -0.07 per share.
| Cash & Cash Equivalents | 58.28M |
| Total Debt | 60.23M |
| Net Cash | -1.95M |
| Net Cash Per Share | -0.07 |
| Equity (Book Value) | -11.12M |
| Book Value Per Share | -0.41 |
| Working Capital | 35.54M |
Cash Flow
In the last 12 months, operating cash flow was -100.02 million and capital expenditures -38,000, giving a free cash flow of -100.05 million.
| Operating Cash Flow | -100.02M |
| Capital Expenditures | -38,000 |
| Free Cash Flow | -100.05M |
| FCF Per Share | -3.73 |
Margins
| Gross Margin | n/a |
| Operating Margin | -28,891.71% |
| Pretax Margin | -25,340.67% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SYRS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -31.77% |
| Shareholder Yield | -31.77% |
| Earnings Yield | -455,674.09% |
| FCF Yield | -466,104.54% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 19, 2022. It was a reverse split with a ratio of 0.1.
| Last Split Date | Sep 19, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
SYRS has an Altman Z-Score of -15.52. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -15.52 |
| Piotroski F-Score | n/a |